NCT05154201 - Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care. | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

January 30, 2023

Study Completion Date

January 30, 2025

Conditions

Effect of Drug

Interventions

DRUG

ORIN1001

Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.

Trial Locations (13)

100142

Beijing Cancer Hospital, Beijing

130000

Jilin Cancer Hospital, Changchun

Harbin Medical University Cancer Hospital, Jilin

150000

Harbin medical University Cancer Hospital, Harbin

Harbin Medical University Cancer Hospital, Heilongjiang

200433

Shanghai Pulmonary Hospital, Shanghai

215006

The First Affiliated Hospital of Soochow University, Jiangse

The First Affiliated Hospital of Soochow University, Suzhou

250000

Shandong Provincial Cancer Hospital, Jinan

Shandong Provincial Cancer Hospital, Shandong

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang